The browser you are using is not supported by this website. All versions of Internet Explorer are no longer supported, either by us or Microsoft (read more here: https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Please use a modern browser to fully experience our website, such as the newest versions of Edge, Chrome, Firefox or Safari etc.

No evidence for higher risk of cancer in patients with multiple sclerosis taking cladribine.

På svenska

Author

  • Julia Pakpoor
  • Giulio Disanto
  • Daniel R Altmann
  • Sue Pavitt
  • Benjamin P Turner
  • Monica Marta
  • Gunnar Juliusson
  • David Baker
  • Jeremy Chataway
  • Klaus Schmierer

Summary, in English

To compare the cancer risk of cladribine and other disease-modifying drugs (DMDs) in trials of people with relapsing multiple sclerosis (pwRMS).

Department/s

  • Stem Cell Center
  • BioCARE: Biomarkers in Cancer Medicine improving Health Care, Education and Innovation

Publishing year

2015

Language

English

Publication/Series

Neurology: Neuroimmunology and NeuroInflammation

Volume

2

Issue

6

Document type

Journal article

Publisher

Lippincott Williams & Wilkins

Topic

  • Neurology

Status

Published

ISBN/ISSN/Other

  • ISSN: 2332-7812